Drug intelligence / Profile preview

amlodipine + levosulpiride

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

**Amlodipine + levosulpiride** is a fixed-dose combination drug containing two active pharmaceutical ingredients: amlodipine, a dihydropyridine calcium channel blocker used primarily to treat hypertension and angina, and levosulpiride, a substituted benzamide antipsychotic that is also classified as a prokinetic agent for gastrointestinal disorders. - **Amlodipine** blocks L-type calcium channels in vascular smooth muscle, leading to vasodilation and a reduction in blood pressure. - **Levosulpiride** acts as a dopamine D2 receptor antagonist, which provides both antipsychotic effects in psychiatric indications and prokinetic effects in gastrointestinal motility disorders by enhancing gastric emptying and intestinal transit. There is no evidence from the provided search results of a widely marketed or regulatory-approved fixed-dose combination product specifically named "amlodipine + levosulpiride." Both drugs are, however, available and sometimes prescribed together for comorbid conditions, such as hypertension with gastrointestinal symptoms like dyspepsia or GERD, particularly in some countries. Fixed-dose combinations of amlodipine with other cardiovascular drugs, and levosulpiride with other GI medications, are frequently marketed, but there are no widely recognized fixed-branded or generic fixed formulations of this exact combination.

Other names
amlodipine and levosulpirideamlodipine plus levosulpiride
02

Targets

LTCC (Voltage-gated calcium channel (L-type))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on amlodipine + levosulpiride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + levosulpiride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call